Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 82,827 shares, a growth of 1,724.4% from the June 15th total of 4,540 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily volume of 262,246 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Sonoma Pharmaceuticals Stock Performance

NASDAQ SNOA remained flat at $1.26 on Friday. The company’s stock had a trading volume of 101,758 shares, compared to its average volume of 173,805. Sonoma Pharmaceuticals has a 52-week low of $0.85 and a 52-week high of $6.92. The stock’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $2.22. The company has a market capitalization of $6.04 million, a P/E ratio of -0.67 and a beta of 1.27.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The company had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned 0.66% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.